Pharmaceuticals · NYSE

PFEPfizer Inc

Last close
$28.89 +0.2%
52-week range
$23.62 to $31.44
Market cap
$165B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$62.6B
-2% vs FY24
Net income
$7.77B
-3% vs FY24
Free cash flow
$9.07B
-8% vs FY24
Net cash
-$54.3B
Cash $10.3B, debt $64.6B

Stock price

-9% since Dec 2016

Valuation vs its own 10 years

Below its 10-year median on 2 of 4 multiples

Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.

P/E, trailing
41.2x
8.0x77.0x
97th percentile, above its median of 17.9x
Positive-earnings quarters only
Price / sales
2.6x
2.2x4.2x
36th percentile, below its median of 2.7x
EV / EBITDA
16.1x
8.3x40.7x
64th percentile, above its median of 12.1x
Price / free cash flow
14.0x
8.3x34.5x
38th percentile, below its median of 14.8x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-27. Every figure carries its unit.

Valuation

P/E
41.2x
Earnings yield
2.4%
Price / sales
2.6x
Price / book
1.9x
Price / operating cash flow
11.6x
EV / EBITDA
16.1x
EV / sales
3.4x
Free cash flow yield
7.2%

Profitability

Gross margin
73.4%
Operating margin
n/a
Net margin
6.3%
Return on equity
4.5%
Return on capital
n/a

n/a: Not reported

Growth per year

Revenue, 3 years
-14.8%
Revenue, 5 years
+8.5%
Revenue, 9 years
n/aNot reported
EPS, 3 years
-37.1%

Balance sheet

Cash and investments
$10.9B
Total debt
$62.6B
Net cash
-$51.7B
Debt / equity
0.70x
Current ratio
1.42x

Shares and dividend

Shares outstanding
5.70B
Share count, 5 years
+1.4%
Beta, 1 year
0.26
Dividend yield
6.0%
Dividend per share, TTM
$1.72
Payout ratio
n/aNot meaningful

Ten years of the business

Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $16.6B
RevenueNet income
Gross profitLatest quarter $12.6B
EBITDALatest quarter $5.62B
Margins76 / 20%
GrossOperatingNet
Earnings per shareLatest quarter $0.56
Cash flowLatest quarter $5.38B
OperatingCapexFree
Cash vs debtLatest quarter $10.9B
Cash and investmentsTotal debt
P/E historyNow 41.2x
P/E, median 17.9x dashed
P/S historyNow 2.6x
P/S, median 2.7x dashed

Where the revenue comes from

US went from 47% to 59% of revenue in 2 years

Share of revenue by region, fiscal 2023 to 2025, as reported in the 10-K.

USInternational Developed MarketsInternational Emerging Markets
FY23
47%35%18%
$59.6B
FY24
61%25%14%
$63.6B
FY25
59%26%15%
$62.6B
Fiscal 2025 by region
RegionRevenueSharevs FY24
US$37.1B59.2%-4%
International Developed Markets$16.2B25.9%+1%
International Emerging Markets$9.31B14.9%+5%

Pharmaceuticals peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
LLY ELI LILLY & Co $1.36T +46% n/a46.8x15.7x 60th percentile
JNJ Johnson & Johnson $688B +8% n/a43.4x6.9x 90th percentile
MRK Merck & Co., Inc. $364B +5% n/a152x5.4x 98th percentile
PFE Pfizer Inc $165B +1% n/a41.2x2.6x 97th percentile
BMY Bristol Myers Squibb Co $130B +4% n/a14.1x2.6x 13th percentile
TEVA Teva Pharmaceutical Industries Ltd $51.9B -16% 10.2%103x3.7x Not enough history

The company

Sector
Health Care
Industry
Pharmaceuticals
CEO
Albert Bourla
Employees
78,500 (as of 2020)
Founded
1849
Headquarters
New York, NY
Fiscal year ends
December
Website
pfizer.com

What it does

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America.

Description from Wikipedia (CC BY-SA).

Around the numbers

What the rest of EdgeStacker knows about PFE.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 2,519 active funds. Crowd level: quiet.

Open the Smart money tab